the aid library

LIST OPTIONS

Filter

7175

Special edition: HIV in MSM

I. Steffens; K. Hagmaier; K. Wilson; et al. Eurosurveillance (Europe’s journal on infectious disease epidemiology, prevention and control); European Centre for Disease Prevention and Control (2015) C2

Eurosurveillance Impact Factor 5.7 June 2015 www.eurosurveillance.org Featuring a series of articles on HIV and STI epidemiology, prevention and control among MSM in Europe

External Link

Guideline on when to start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV

Elaine Abrams, Tsitsi Apollo, Janet Bhila et al. World Health Organization WHO (2015) C_WHO

The new WHO guidelines recommend that people living with HIV be started on antiretrovirals (ARVs) as soon as possible after being diagnosed. Currently, many people living with the virus globally must wait until their CD4 counts fall to 500 to start treatment. According to the WHO, the move to early ... more

External Link

Standard Treatment Guidelines and Essential Medicines List of Common Medical Conditions

Government of the Kingdom of Swaziland Ministry of Health (2012) C2

The product of all this work is the Standard Treatment Guideline and Essential Medicines List of Common Medical Conditions in the Kingdom of Swaziland. These systematically developed statements are designed to assist practitioners in making decisions about appropriate treatment for specific clinical... more

Download (625)

View PDF (838)

National Guidelines for HIV and AIDS Treatment and Care in Adolescents and Adults

Federal Ministry of Health Nigeria , World Health Organisation (WHO) (2010) C_WHO

External Link

Keeping community health workers in Uganda motivated: key challenges, facilitators, and preferred program inputs

Bruniea, A.; P. Wamala-Mucheri, C. Otterness, et al. (2014) CC

Glob Health Sci Pract February 1, 2014 vol. 2 no. 1 p. 103-116

Download (578)

View PDF (695)

Zoonotic diseases of public health importance

National Institue of communicable Diseases, India (1998) C1

Download (975)

View PDF (851)

Nepal: Statistics & Information of MDR and XDR TB in SAARC Region

SAARC TB and HIVAIDS Centre (STAC) (2016) C1

Download (235)

View PDF (241)

Principles in using psychotropic medication in children and adolescents

B. Vitiello IACAPAP (2012) C2

Introduction Chapter A.7

Download (195)

View PDF (220)

Interventions for carers of people with dementia

World Health Organization (2012) C_WHO

Q9: For carers of people with dementia, do interventions (psychoeducational, cognitive-behavioural therapy counseling/case management, general support, training of caregivers, multi-component interventions and miscellaneous interventions) when compared to placebo/comparator, produce benefits/harm in... more

Download (161)

View PDF (209)

Guidelines for COVID-19 testing and quarantine of air travellers - Addendum to the Aviation Health Safety Protocol

European Centre for Disease Prevention and Control ECDC (2020) CC

This joint ECDC-European Union Aviation Safety Agency (EASA) document aims to support Member States in determining a coordinated approach to reduce the risks related to the movement of people by air within and between the EU/EEA countries and the UK in the context of the COVID-19 pandemic, noting th... more

Download (280)

View PDF (260)

Monitoring and surveillance of antimicrobial resistance in bacteria from healthy food animals intended for consumption

Food and Agriculture Organization of the United Nations FAO (2019) C2

The animal health subsector within the agriculture sector is the gatekeeper of antimicrobial resistance (AMR) in livestock, aquaculture, animal products, and the immediate animal environment. In support of member countries taking responsibility for and moving forward with putting AMR monitoring and ... more

Download (380)

View PDF (599)

Trends in Child Health in Nigeria, 2003– 2013

Winter, Rebecca, Akinlo, Ambrose, and Lia Florey ICF International (2016) C2

DHS Further Analysis Reports No. 103

Download (687)

View PDF (1327)

WHO recommendations on the management of diarrhoea and pneumonia in HIV-infected infants and children

World Health Organization (2010) C_WHO

To improve survival and quality of life among the 2.5 million children living with HIV, a comprehensive package of prevention, care and treatment is required. This package should include management of infections such as pneumonia, diarrhoea, malaria and ear infections, as well as common opportunisti... more

Download (308)

View PDF (331)

WHO operational handbook on tuberculosis: module 2: screening: systematic screening for tuberculosis disease

World Health Organization WHO (2020) C_WHO

Download (160)

View PDF (164)

Global Epidemiological Surveillance Standards for Influenza

World Health Organization WHO (2013) C_WHO

Download (182)

View PDF (202)

Nurses as substitutes for doctors in primary care - Review

Laurant M, van der Biezen M, Wijers N et al. Cochrane Library (2018) CC

Current and expected problems such as ageing, increased prevalence of chronic conditions and multi-morbidity, increased emphasison healthy lifestyle and prevention, and substitution for care from hospitals by care provided in the community encourage countries worldwide to develop new models of prima... more

Download (507)

View PDF (1117)

The Wise List 2015

Stockholm Drug and Therapeutics Committee (2015) C_WHO

with recommended essential medicines for common diseases in patients in Stockholm County Council (Healthcare Region), Sweden

Download (764)

View PDF (1571)

Guidance on oral pre-exposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstratio

World Health Organization (2012)

Download (205)

View PDF (241)

EMTCT Plus - Framework for Elimination of Mother-to-Child Transmission of HIV, Syphilis, Hepatitis B, and Chagas

F. Pérez; M. B. Mello; L. Sereno; et al. Pan American Health Organization; World Health Organization (2017) C_WHO

The objective of the EMTCT Plus initiative is to achieve and sustain the elimination of mother-to-child transmission of HIV, syphilis, Chagas, and perinatal hepatitis B (HBV) as a public health threat. It embraces the principles and lines of action of the Strategy for Universal Access to Health a... more

Download (346)

View PDF (456)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more